Economic analysis: Randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer
Objective: Given the economic burden of prostate cancer (PCa), a PCa risk-reduction medication would be desirable. A within-trial economic analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was performed. <br><br>Methods: REDUCE, a 4-year, randomized, double-blind, placebo-controlled, parallel-group clinical trial, compared efficacy and safety of dutasteride 0.5 mg daily and placebo to reduce the risk of PCa in men at increased risk. Resource use was prospectively collected; costs from standard costing sources were applied. Utilities were obtained from published literature. Relative risks and Wilcoxon rank sums were used to examine differences<br>between treatments.<br><br>Results: Placebo patients were at significantly higher risk (P < 0.05) for concomitant medication use; and health care visits related to surgical procedures, unscheduled biopsies, acute urinary retention, urinary tract infections, or macroscopic hematuria. Total costs were significantly lower (P < 0.001) in dutasteride patients ($1 300; 95% confidence interval: $806, $1 795). Incremental cost per quality-adjusted life-year (QALY) was $26 516; cost per PCa case avoided was $19.<br><br>Conclusions: During the 4-year trial period, men at increased risk for PCa receiving dutasteride incurred fewer<br>health care costs than men receiving placebo, which helped offset dutasteride costs. Dutasteride was good value<br>for money.
Chirila, C., Earnshaw, S., Black, L., McDade, C., Roskell, N., Shannon, P., ... Andriole, G. L. (2011). Economic analysis: Randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. Journal of Acquired Immune Deficiency Syndromes, S3, 004.